Product Segment to Hold North America Radiotherapy Market Share During 2023-2031<br><br> <br><br>According to our new research study on " North America Radiotherapy Market Size and Forecast (2021-2031), Regional Share, Trend, and Growth Opportunity Analysis," the market value is projected to grow from US$ 3,849.52 million in 2023 to US$ 8,457.84 million by 2031. The North America radiotherapy market is further anticipated to record a CAGR of 10.3% from 2022 to 2030. The North America radiotherapy market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies.<br><br> Aging populations, lifestyle factors such as tobacco use, unhealthy diets, sedentary lifestyles, and environmental exposures to carcinogens are a few factors leading to the rise in cancer cases. With the rise in the number of people being diagnosed with cancer, there is an increasing need for efficient treatment choices such as radiation. Because of its many uses, radiation therapy is a vital component of a comprehensive cancer treatment plan. When surgery is not possible or as effective, radiotherapy might be used as the main treatment for cancer. It can also be administered in conjunction with immunotherapy, chemotherapy, or surgery to improve treatment results. Thus, the rising prevalence of cancer boosts the growth of the North America radiotherapy market.<br><br>The US holds a significant share of the North America radiotherapy market. The market growth in the US is driven by the growing digitalization of medical devices, increasing adoption of advanced medical device technologies, growing emphasis on improving treatment outcomes, and rising prevalence of cancer. According to a study published by the American Cancer Society in 2024, approximately 13,820 women in the US were diagnosed with cervical cancer. <br><br>An increasing number of business activities among market players contribute to the market growth. In November 2020, SOFIE Biosciences, Inc. and Jubilant Radiopharma entered a strategic partnership to expand its US production capacity and distribution channel. Further, in January 2021, Eckert & Ziegler announced its plan to build a cGMP facility for radiopharmaceutical services in the US. <br><br>There are several initiatives by the government and healthcare authorities to encourage the adoption of radiotherapy. Such strategies are likely to have a constructive impact on the US radiotherapy market. For instance, in June 2020, the American Society for Radiation Oncology (ASTRO) introduced new clinical guidelines regarding radiotherapy for nonmetastatic cervical cancer. The new guideline focuses on precisely implementing steps and processes to conduct radiation therapy. All these factors are expected to fuel the US radiotherapy market by 2031<br><br> <br><br>Based on type, the North America radiotherapy market is divided into segmented into products and software. The products segment held largest market share in 2023. <br><br>By application, the market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, lymphoma, liver cancer, thyroid cancer, brain cancer, cervical cancer, spine cancer, and others. The breast cancer segment held the largest share of the market in 2023.<br><br>In terms of end user, the market is categorized into hospitals, radiation therapy centers, and specialty clinics. The hospitals segment dominated the market in 2023.<br><br>Siemens Healthineers AG, Accuray Incorporated, Sumitomo Heavy Industries Ltd, Elekta AB, Hitachi Ltd, Koninklijke Philips NV, Brainlab AG, and PROTOM INTERNATIONAL. are a few key companies profiled in the North America radiotherapy market report. <br><br>Companies operating in the North America radiotherapy market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the North America radiotherapy market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall North America radiotherapy market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.<br><br> <br><br>A few of the significant developments by key market players are listed below.<br><br> <br><br><li>    Elekta received FDA approval for Elekta Esprit, a new Leksell Gamma Knife radiosurgery platform. This milestone makes the system available to clinicians and people with brain disease in the U.S., as well as opening the door to other countries where FDA approval is recognized. (Source: Elekta, Press Release, 2022)<br><br><li>    Royal Philips launched two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation. The company's artificial intelligence (AI) enabled MRCAT Head and Neck radiotherapy application, which allows the use of MR as the sole or primary imaging modality for radiotherapy planning in the treatment of soft tissue tumors in the head and neck, along with the brain, pelvis and prostate, has received FDA 510(k) clearance and is commercially available in the U.S. (Source: Royal Philips, Press Release, 2022)

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com